Encinitas, California–(Newsfile Corp. – April 27, 2023) – Kiora Pharmaceuticals (NASDAQ: KPRX) presented preliminary results from an ongoing clinical trial showing its investigational drug, KIO-301, has the potential to restore light perception in patients who are blind or living with ultra-low vision due to retinitis pigmentosa. KIO-301 is a light-sensing…Read More
Kioras Investigational Treatment for Retinitis Pigmentosa KIO301 Demonstrates Visual Function Restoration in Patients Who Are Blind
